A Pharmacokinetics (PK) Study in Healthy Adults

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 17, 2025

Primary Completion Date

April 7, 2025

Study Completion Date

April 7, 2025

Conditions

Blepharoptosis

Interventions

DRUG

STN1013800 ophthalmic solution

Investigational Product: 0.1% STN1013800 ophthalmic solution once daily (QD) (9AM ± 60 min), one drop for each eye

Trial Locations (1)

Beijing Chaoyang Hospital, Capital Medical University, Beijing

All Listed Sponsors

lead

Santen Pharmaceutical Co., Ltd.

INDUSTRY

NCT06911216 - A Pharmacokinetics (PK) Study in Healthy Adults | Biotech Hunter | Biotech Hunter